A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Objective: To determine the efficacy and safety of eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS), compared with current treatment options. Design: A systematic review was performed according to the general principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. All study designs were included, except case histories. Participants: All patients diagnosed with aHUS were included; no age restrictions were used. Interventions: Eculizumab compared with current treatment options. Identification of studies: 12 databases were searched. Additional searches were performed through the Food and Drug Administration (FDA) and the Electronic Medicines Compendium websites, Google internet searches and contacting clinical experts. Reference lists of relevant articles were checked for additional studies. Results: 2 small, uncontrolled prospective multinational, multicentre studies and one small uncontrolled multinational, multicentre retrospective study were included. No meta-analyses were performed. Compared with baseline measures, thrombotic microangiopathy event-free status was achieved in 84% of patients in the prospective studies. Adverse events, as documented by enrolling investigators were frequent, with upper-respiratory tract infection affecting a third of patients. No deaths or episodes of meningitis or meningococcal septicaemia occurred in the prospective studies. Results of the study extension phases up to 114 weeks indicate that the benefits of the treatment are sustained. Conclusions: Eculizumab is clinically effective for the treatment of aHUS. Further research is needed to evaluate eculizumab, ideally using patient-related clinical outcomes. If randomised studies are not feasible, study investigators should ensure that the threat of bias is minimised in future studies of eculizumab with respect to the reporting of patient recruitment and selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Hematological Problems in Pediatric Intensive Care
Revel-Vilk, S., Cox, P., Robitaille, N., & Blanchette, V. (2014) · Pediatric and Adolescent Medicine · doi:10.1159/000350346 · Cited by 3,508
Non-Transgenic Mouse Models of Kidney Disease
Rabe, M., & Schaefer, F. (2016) · Nephron · doi:10.1159/000445171 · Cited by 1,922
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042 · cited 1×
“Patients with CD46 mutations have a better long-term outcome, with 30% progressing to ESRD, despite a frequently relapsing course.(13) The mortality rate is higher in children than in adults (6.”
BackgroundCaprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C., Bresin, E., Cassis, L., Gamba, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-007252 · Cited by 732 · cited 1×
“48 There is also potential for publication bias in evaluating the retrospective study.”
BackgroundFremeaux-Bacchi, V., Fakhouri, F., Garnier, A., Bienaimé, F., Dragon-Durey, M.-A., Ngo, S., Moulin, B., Servais, A., Provot, F., Rostaing, L., et al. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04760512 · Cited by 714 · cited 1×
“7 However, there are some indications for caution with a longer term use of eculizu-mab.”
BackgroundAtypical hemolytic uremic syndrome
Loirat, C., & Frémeaux-Bacchi, V. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-60 · Cited by 669
Gasser, C., GAUTIER, E., STECK, A., SIEBENMANN, R. E., & Oechslin, R. (1955) · PubMed · Cited by 553
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome
Lemaire, M., Frémeaux-Bacchi, V., Schaefer, F., Choi, M., Tang, W. H., Le Quintrec, M., Fakhouri, F., Taque, S., Nobili, F., Martinez, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2590 · Cited by 483
Eculizumab in Severe Shiga-Toxin–Associated HUS
Lapeyraque, A.-L., Malina, M., Fremeaux-Bacchi, V., Boppel, T., Kirschfink, M., Oualha, M., Proulx, F., Clermont, M.-J., Le Deist, F., Niaudet, P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1100859 · Cited by 423
Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy
Ram, S., Lewis, L. A., & Rice, P. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00048-09 · Cited by 405 · cited 1×
“57 Consequently, protection against meningococcal disease by antibody-mediated killing becomes essential.”
BackgroundHillmen, P., Muus, P., Röth, A., Elebute, M. O., Risitano, A. M., Schrezenmeier, H., Szer, J., Browne, P., Maciejewski, J. P., Schubert, J., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12347 · Cited by 394 · cited 1×
“It was originally tested for rheumatoid arthritis without success, but is now used routinely for paroxysmal nocturnal haemoglobinuria (PNH).(23) It is licensed by the European Medicines Agency (EMA), and the US Food and Drug Administration (FDA) for treatment of aHUS.”
BackgroundGuideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome
The European Paediatric Study Group for HUS, Ariceta, G., Besbas, N., Johnson, S., Karpman, D., Landau, D., Licht, C., Loirat, C., Pecoraro, C., Taylor, C. M., et al. (2009) · Pediatric Nephrology · doi:10.1007/s00467-008-0964-1 · Cited by 352
Eculizumab for Atypical Hemolytic–Uremic Syndrome
Nürnberger, J., Philipp, T., Witzke, O., Saez, A. O., Vester, U., Baba, H. A., Kribben, A., Zimmerhackl, L. B., Janecke, A. R., Nagel, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0808527 · Cited by 346
Besbas, N., Karpman, D., Landau, D., Loirat, C., Proesmans, W., Remuzzi, G., Rizzoni, G., Taylor, C. M., Van de Kar, N., & Zimmerhackl, L. B. (2006) · Kidney International · doi:10.1038/sj.ki.5001581 · Cited by 277 · cited 1×
“Establishing global patient registries, or utilising data from the International Registry of Recurrent and Familial HUS established in Italy 3 would provide insights into the natural history of this rare disease.”
MethodTaylor, C. M., Machin, S., Wigmore, S. J., Goodship, T. H. J., & on behalf of a working party from the Renal Association, T. B. C. F. S. I. H. A. T. B. T. S. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07916.x · Cited by 277 · cited 1×
“dence of aHUS to be 2 per million population and prevalence as 7 cases per million in children.(6) Recent data have shown that the onset of aHUS is as frequent in adulthood (58.”
BackgroundEculizumab for Congenital Atypical Hemolytic–Uremic Syndrome
Gruppo, R. A., & Rother, R. P. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0809959 · Cited by 275 · cited 1×
“The initial two case reports of treatment of aHUS with eculizumab were published in the N Engl J Med in 2009 49 50 and have been followed by numerous other positive case reports which have contributed signi fi cantly to the fi eld in informing best use of eculizumab.”
BackgroundCampistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyó, J. M., Macía, M., Mendizábal, S., Praga, M., et al. (2015) · Nefrología · doi:10.1016/j.nefro.2015.07.005 · Cited by 272 · cited 1×
“22 51 However, it is less clear if negative data would be similarly published.”
BackgroundHoward, J. F., Barohn, R. J., Cutter, G. R., Freimer, M., Juel, V. C., Mozaffar, T., Mellion, M. L., Benatar, M. G., Farrugia, M. E., Wang, J. J., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23839 · Cited by 225
Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes, D. A., Tunnage, B., & Yeo, S. T. (2005) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hci128 · Cited by 219
New insights into postrenal transplant hemolytic uremic syndrome
Zuber, J., Le Quintrec, M., Sberro-Soussan, R., Loirat, C., Frémeaux-Bacchi, V., & Legendre, C. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.155 · Cited by 196
Georges, A., Bonneau, J., Bonnefont-Rousselot, D., Champigneulle, J., Rabès, J. P., Abifadel, M., Aparicio, T., Guenedet, J. C., Bruckert, E., Boileau, C., et al. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-1 · Cited by 175
Renal function and survival in 200 patients undergoing ECMO therapy
Kielstein, J. T., Heiden, A. M., Beutel, G., Gottlieb, J., Wiesner, O., Hafer, C., Hadem, J., Reising, A., Haverich, A., Kühn, C., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs398 · Cited by 175 · cited 1×
“…Escherichia coli O157-mediated Stx-HUS, 52 the summary of results from a large subgroup of adults affected with E coli O104-mediated Stx-HUS (n=491) 53 54 was that eculizu-mab and PE (n=193) offered no additional advantage compared to PE (n=241) or to best practice supportive care alone (n=57) in…”
Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome
Saland, J. M., Ruggenenti, P., & Remuzzi, G. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008080906 · Cited by 165 · cited 1×
“Attempts to overcome this issue included a small number of reports of renal transplantation with the addition of long-term PE(15) or use of combined liver–kidney transplantation.(21) Liver–kidney transplantation has been successful, but has a significant procedural morbidity rate and risk of death.”
BackgroundPathology after Eculizumab in Dense Deposit Disease and C3 GN
Herlitz, L., Bomback, A. S., Markowitz, G. S., Stokes, M. B., Smith, R. N., Colvin, R. B., Appel, G. B., & D’Agati, V. D. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011121186 · Cited by 155
Michael, M., Elliott, E. J., Craig, J. C., Ridley, G. F., & Hodson, E. M. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.038 · Cited by 123 · cited 5×
“It is therefore necessary to examine this question in a formal RCT looking at children and adults diagnosed with Stx-HUS.”
BackgroundResultInfluentialChambers, D., Rodgers, M., & Woolacott, N. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.12.010 · Cited by 121 · cited 3×
“The prospective studies identi fi ed by the search were appraised using checklist criteria for non-randomised studies adapted from Chambers.”
MethodInfluentialMeningococcal Sepsis Complicating Eculizumab Treatment Despite Prior Vaccination
Struijk, G. H., Bouts, A. H. M., Rijkers, G. T., Kuin, E. A. C., ten Berge, I. J. M., & Bemelman, F. J. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12032 · Cited by 119 · cited 3×
“All patients need to be vaccinated against Neisseria meningitidis and many physicians also provide antibiotic prophylaxis, for example with cipro-fl oxacin 58 as the commonest European meningococcal serotype, (type B), is not included in the tetravalent vaccine.”
BackgroundInfluentialHemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder
Sharma, A. P., Greenberg, C. R., Prasad, A. N., & Prasad, C. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0604-1 · Cited by 116
An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document
Campistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyo, J. M., Macia, M. L., Mendizábal, S., Praga, M., et al. (2015) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2015.11.006 · Cited by 100
Schmidtko, J., Peine, S., Housseini, Y. E., Pascual, M. A., & Meier, P. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.028 · Cited by 97 · cited 1×
“It is licensed by the European Medicines Agency (EMA), and the US Food and Drug Administration (FDA) for treatment of aHUS.(24) The”
BackgroundThe Canadian apheresis registry
Rock, G. A., Clark, B., & Sutton, D. (2003) · Transfusion and Apheresis Science · doi:10.1016/s1473-0502(03)00111-3 · Cited by 82
Lindorfer, M. A., Pawluczkowycz, A. W., Peek, E. M., Hickman, K., Taylor, R. P., & Parker, C. J. (2010) · Blood · doi:10.1182/blood-2009-09-244285 · Cited by 81
Risitano, A. M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4118-2_10 · Cited by 76 · cited 2×
“…increased clearance through the reticuloendothelial system and has led to recurrent anaemia and transfusion requirement in some patients with PNH. 44 45 Second, renal biopsy performed in three patients with either dense deposit disease or C3 glomerulopathy before and after eculizumab treatment…”
BackgroundVaccination against hepatitis B infection in patients with end stage renal disease
Bel'eed, K., Wright, M., Eadington, D. W., Farr, M., & Sellars, L. (2002) · Postgraduate Medical Journal · doi:10.1136/pmj.78.923.538 · Cited by 75 · cited 1×
“Patients on dialysis have poor response to vaccinations, for example, failed seroconversion and loss of immunity with time after hepatitis B vaccination.(60) Following completion of the systematic review, the Advisory Group for National Specialised Services in the UK has advised government ministers that there is evid…”
BackgroundThrombotic Microangiopathy: Current Knowledge and Outcomes With Plasma Exchange
Clark, W. F. (2012) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2011.01035.x · Cited by 71 · cited 2×
“Overall, plasmapheresis is a safe procedure with a mortality rate of less than 1 in 10 000 PE procedures.(14) 17 Potential complications include risks associated with vas-”
BackgroundTransplantation in Atypical Hemolytic Uremic Syndrome
Kavanagh, D., Richards, A., Goodship, T. H. J., & Jalanko, H. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1262887 · Cited by 54 · cited 1×
“As such, isolated renal transplantation cannot normally be recommended.(20) Attempts to overcome this issue included a small number of reports of renal transplantation with the addition of long-term PE(15) or use of combined liver–kidney transplantation.”
Self-citationElston, J., & Taylor, R. S. (2009) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462309090023 · Cited by 47 · cited 1×
“endpoints in order to predict clinical benefit, these should be validated to demonstrate the relationship between surrogate and patient-related outcome.(56) The safety data indicated that adverse events in the uncontrolled prospective studies are frequent, with hypertension and upper respiratory tract infection affect…”
BackgroundComplement disorders and hemolytic uremic syndrome
Joseph, C., & Gattineni, J. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32835df48a · Cited by 42
Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013
Carter, C. E., & Benador, N. M. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2479-7 · Cited by 30
Complement activation in thrombotic microangiopathy
Tati, R., & Karpman, D. (2013) · Hämostaseologie · doi:10.5482/hamo-12-12-0025 · Cited by 22 · cited 1×
“…coli O157-mediated Stx-HUS, 52 the summary of results from a large subgroup of adults affected with E coli O104-mediated Stx-HUS (n=491) 53 54 was that eculizu-mab and PE (n=193) offered no additional advantage compared to PE (n=241) or to best practice supportive care alone (n=57) in a…”
Zlamy, M., Hofer, J., Elias, J., Vogel, U. F., Frosch, M., Jungraithmayr, T., Zimmerhackl, L. B., & Prelog, M. (2011) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2011.01585.x · Cited by 20 · cited 1×
“further transplant patient had waning but protective titres to meningococcus C vaccination.(59) Therefore, if eculizumab becomes used more widely to facilitate”
Atypical HUS: time to take stock of current guidelines and outcome measures?
Rees, L. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2423-x · Cited by 15
INF2 Is Another Piece of the Jigsaw Puzzle for FSGS
Pei, Y. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010121293 · Cited by 15
Arias, D. P., García‐Cazorla, À., Ortiz, J., Jou, C., Cusí, V., Suñol, M., Toll, T., Perez, B., Ormazábal, A., Fowler, B., et al. (2012) · JIMD Reports · doi:10.1007/8904_2012_161 · Cited by 12
Greenbaum, L. A., Legendre, C. M., Babu, S., Furman, R. R., Sheerin, N., Cohen, D. J., Eitner, F., Delmas, Y., Bedrosian, C. L., & Loirat, C. (2012) · Blood · doi:10.1182/blood.v120.21.2084.2084 · Cited by 10 · cited 1×
“Follow-up data at week 100 (study C08-002) Thirteen patients entered the extension phase and data analysis was reported on ITT population (n=17).(42) Mean platelet count was significantly improved at 2-year follow-up with 15 patients (88%) achieving and maintaining a platelet count of (≥150×10(9)/L).”
MethodGreenbaum, L. A., Babu, S., Furman, R. R., Sheerin, N., Cohen, D. J., Gaber, A. O., Eitner, F., Delmas, Y., Loirat, C., Bedrosian, C. L., et al. (2011) · Blood · doi:10.1182/blood.v118.21.193.193 · Cited by 10
Licht, C. P. B., Muus, P., Legendre, C. M., Douglas, K., Hourmant, M., Delmas, Y., Herthelius, M., Trivelli, A., Goodship, T. H. J., Bedrosian, C. L., et al. (2012) · Blood · doi:10.1182/blood.v120.21.985.985 · Cited by 9
Goodship, T. H. J., Muus, P., Legendre, C., Douglas, K., Hourmant, M., Delmas, Y., Herthelius, M., Trivelli, A., Loirat, C., Bedrosian, C., et al. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.06.368 · Cited by 3
Loirat, C., Babu, S., Zimmerhackl, L. B., Legendre, C. M., Furman, R. R., Sheerin, N., Cohen, D., Gaber, A. O., Eitner, F., Delmas, Y., et al. (2011) · RWTH Publications (RWTH Aachen) · Cited by 1
Research works printed but not linked: 7
- 1. Gasser C, Gautier E, Steck A, et al. Hamolytisch-uramische syndrome: bilateral Nierenrindennekrosen bei akuten erworbenen hamolytischen Anamien. Schweiz Med Wochenschr 1955;85:905.
- 27. Legendre C, Babu S, Furman R, et al. Safety & efficacy of eculizamab in aHUS patients resistant to plasma therapy: interim analysis from a phase II trial. J Am Soc Nephrol 2011;21:201.
- 32. Licht C, Muus P, Legendre C, et al. A phase II study of eculizumab in adolescent/adult patients with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange/infusion: interim efficacy and safety analysis. Pediatr Nephrol 2011;26:1591-731.
- 35. Licht C, Muus P, Legendre C, et al. A phase II study of eculizumab in patients with atypical hemolytic uremic syndrome (AHUS) receiving chronic plasma exchange/infusion: interim analysis. J Thromb Haemost 2011;9(s2):499-711.
- 38. Simonetti GD, Gruppo RA, Rodig N, et al. Eculizumab therapy for atypical hemolytic uremic syndrome (aHUS) in pediatric patients: efficacy and safety outcomes from a retrospective study. Pediatr Nephrol 2011;26:1663.
- 40. Licht C, Muus P, Legendre C, et al. Ph II study of eculizumab (ECU) in patients (PTS) with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange/infusion (PE/PI). J Am Soc Nephrol 2011;22:197.
- 43. Hillmen P, Hall C, Marsh J, et al. Eculizumab, a C5 complement-blocking antibody, controls hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) with responses maintained over a prolonged period of therapy. Blood 2003;102:509a-10a.
Cited by
International, F. H., Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., et al. (2016) · Pediatric Nephrology · doi:10.1007/s00467-015-3076-8 · Cited by 596
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics
Garred, P., Tenner, A. J., & Mollnes, T. E. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000072 · Cited by 208
“…found to increase the release of IL-1b and IL-6 when added to Ab amyloid-primed human monocytes in vitro (O’Barr and Cooper, 2000), andC5aR1 antagonists have been found to reduce proinflammatory cytokines like IL-1b in periodontal disease (Hajishengallis and Lambris, 2012; Recknagel et al., 2012).”
BackgroundInfectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 187
“hemolytic uremic syndrome (aHUS) (1203), which is caused by mutations in regulatory”
BackgroundRathbone, J., Hoffmann, T., & Glasziou, P. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0067-6 · Cited by 184
“The trial citations of four systematic reviews [1, 18 – 20] retrieved electronically from biomedical database searches (MEDLINE, EMBASE, CINAHL, Cochrane CENTRAL) were used to evaluate Abstrackr.”
BackgroundMethodSelf-citation
Metadata
- Authors
- Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., & Cantrell, A.
- Affiliations
- University of Sheffield (GB)
- Imperial College London (GB)
- Corresponding author
- Kaltenthaler, Eva
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2013-11
- Volume
- 3
- Issue
- 11
- Pages
- e003573
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC3822313
- OpenAlex
- W2143604857
- Cited by
- 110
- References
- 56
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 5 · 2022: 11 · 2021: 4 · 2020: 9 · 2019: 13 · 2018: 7 · 2017: 9 · 2016: 13 · 2015: 9 · 2014: 10
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc)
- Funders
- Alexion Pharmaceuticals
- Wellcome Trust (WT085226)
- National Institute for Health and Care Research
- Health Technology Assessment Programme
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, atypical hemolytic uremic syndrome, thrombotic microangiopathy, complement inhibition, treatment efficacy, adverse events, upper respiratory tract infection, long-term treatment outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.